1241P Phase Ib study of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors: Tolerability results and antitumor activity in esophageal carcinoma

Muro, K.; Kato, Ken; Chin, Keisho; NISHINO, KAZUMI; Satouchi, Miyako; Watanabe, Yasutaka; Kawakami, Hajime; Tsushima, Takahiro; Hirai, Hiroshi; Chisamore, Michael; Kojima, Takashi

doi:10.1016/j.annonc.2022.07.1359

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 31 Additional clinical studies of combined FGFR and checkpoint inhibition for patients with solid tumors harboring FGF/FGFR alterations are under way. 32 , 33 , 34 , 35 , 36…”

Section: Discussionmentioning

confidence: 99%

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

Saleh,

Barve,

Subbiah

et al. 2024

ESMO Open

View full text Add to dashboard Cite

“… 31 Additional clinical studies of combined FGFR and checkpoint inhibition for patients with solid tumors harboring FGF/FGFR alterations are under way. 32 , 33 , 34 , 35 , 36…”

Section: Discussionmentioning

confidence: 99%

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

Saleh,

Barve,

Subbiah

et al. 2024

ESMO Open

View full text Add to dashboard Cite

Section: Potent Molecular-targeted Therapy For Patients With Esccmentioning

confidence: 99%

“…In a phase Ib trial of futibatinib plus pembrolizumab in advanced or metastatic EC harboring FGFR mRNA overexpression, the interim analysis showed acceptable safety, with an ORR of 44% in ICIs naïve patients and 20% in ICI refractory patients. 273 Src homology 2 domain-containing phosphatase (SHP2) is a non-receptor ubiquitous protein tyrosine phosphatase, 274 which serves as an important hub to connect several intracellular A Ooki, H Osumi et al…”

Section: Therapeutic Advances In Medical Oncologymentioning

confidence: 99%

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma

et al. 2023

View full text Add to dashboard Cite

Esophageal cancer (EC) remains a public health concern with a high mortality and disease burden worldwide. Esophageal squamous cell carcinoma (ESCC) is a predominant histological subtype of EC that has unique etiology, molecular profiles, and clinicopathological features. Although systemic chemotherapy, including cytotoxic agents and immune checkpoint inhibitors, is the main therapeutic option for recurrent or metastatic ESCC patients, the clinical benefits are limited with poor prognosis. Personalized molecular-targeted therapies have been hampered due to the lack of robust treatment efficacy in clinical trials. Therefore, there is an urgent need to develop effective therapeutic strategies. In this review, we summarize the molecular profiles of ESCC based on the findings of pivotal comprehensive molecular analyses, highlighting potent therapeutic targets for establishing future precision medicine for ESCC patients, with the most recent results of clinical trials.

show abstract

“…16,36 Table 1 summarizes the recent clinical trials that have investigated the clinical benefit of nivolumab. 16,20,[36][37][38][39] The ATTRACTION-1 trial…”

Section: Nivolumab As Second-or Later-line Treatmentmentioning

confidence: 99%

“…trial evaluating fusibatinib plus pembrolizumab combination therapy showed an objective response rate of 44% in the ICI-naïve advanced OSCC cohort and 20% in the ICI-refractory advanced OSCC cohort 38. In addition to the mainstream combination of ICIs and chemotherapy for patients with OSCC, the combination of ICIs with molecular-targeted agents is also being assessed.…”

mentioning

confidence: 99%

Nivolumab Combination Therapy for the Treatment of Unresectable Advanced or Metastatic Oesophageal Squamous Cell Carcinoma

Yoshinami¹,

Yamamoto²,

Kato³

2023

Oncology &Amp; Haematology

View full text Add to dashboard Cite

Oesophageal cancer (OC) is the seventh most common malignancy worldwide, and there are few effective treatment options for advanced OC. Fluoropyrimidine and platinum-based chemotherapy has been the standard first-line treatment for advanced oesophageal squamous cell carcinoma (OSCC) but the survival outcomes are poor. Therefore, there is a need to develop new, more effective drugs. Immune checkpoint inhibitors (ICIs) have emerged as a new standard treatment for several malignancies. Nivolumab, a human monoclonal immunoglobulin G4 antibody that inhibits programmed cell death protein-1, has been developed for the treatment of advanced OSCC. Nivolumab monotherapy demonstrated clinical efficacy and safety in patients with OSCC in the ATTRACTION-3 trial, and was approved by the United States Food and Drug Administration as later-line treatment for patients with previously treated OSCC, regardless of programmed cell death protein-1 ligand expression status. Recently, the CheckMate 648 trial demonstrated the efficacy and safety of both an ICI in combination with chemotherapy, and a dual ICI combination, as first-line treatment for patients with advanced OSCC. This review discusses the current status of nivolumab combination therapy for patients with advanced OSCC, and future perspectives.

show abstract

1241P Phase Ib study of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors: Tolerability results and antitumor activity in esophageal carcinoma

Cited by 6 publications

References 0 publications

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma

Nivolumab Combination Therapy for the Treatment of Unresectable Advanced or Metastatic Oesophageal Squamous Cell Carcinoma

Contact Info

Product

Resources

About